Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company's principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in...
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 61 8 6555 2950
Fax: 61 8 6166 0261
Address:
295 Rokeby Road, Suite 1, Subiaco, Australia
